Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

West Virginia University

Status: Completed

Conditions: COVID-19; Acute Respiratory Distress Syndrome

Treatments: Procedure: Stellate Ganglion Block

Study type: Interventional

Funder types: Other

Identifiers

NCT04402840

2004963113

Details and patient eligibility

About

The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.

Full description

Primary Aim:

• To determine safety of stellate ganglion block (SGB) in ARDS

Secondary Aim:

• To determine efficacy of SGB in slowing the progression of ARDS

Enrollment: 5 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects age 18 to 80
• Subjects with PCR documented diagnosis of COVID-19 ARDS requiring critical care and transfer to intensive care unit
• Bilateral opacities consistent with pulmonary edema must be present and may be detected on CT or chest radiograph

Exclusion criteria

• Subjects with pre-existing cardiac failure
• Hemodynamic Instability
• Subject on Extracorporeal membrane oxygenation (ECMO)
• Anatomical inability to do a stellate block

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

Stellate Ganglion Block (SGB)

Experimental group

Description:

Clinical Stellate ganglion block

Treatment:

Procedure: Stellate Ganglion Block